Tisolagiline

Tisolagiline ( ; developmental code names KDS-2010) is a potent, highly selective, and reversible monoamine oxidase B (MAO-B) inhibitor which is under development for the treatment of Alzheimer's disease and obesity.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Tisolagiline ( ; developmental code names KDS-2010) is a potent, highly selective, and reversible monoamine oxidase B (MAO-B) inhibitor which is under development for the treatment of Alzheimer's disease and obesity. It is taken by mouth. Tisolagiline is being developed by NeuroBiogen Co., Ltd.. As of December 2024, it is in phase 2a clinical trials for Alzheimer's disease and obesity.

In 2025, research suggested that KDS-2010 could also be used in recovery of spinal cord injuries. In these injuries, there is an excess of glia cells which protect the site but inhibit neural repair. Use of the MAO-B inhibitor in animal models resulted in improved neurological and locomotor abilities.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1377082665 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

4 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.